Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234935 · ClinicalTrials.gov registry record · Phase 2
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
A Phase 2 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01234935: Completed Phase 2 study, sponsored by Translational Oncology Research International.
NCT01234935 is a Phase 2 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01234935, a Phase 2 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving dasatinib together with gemcitabine hydrochloride is more effective than gemcitabine hydrochloride alone in treating pancreatic cancer. PURPOSE: This randomized phase II trial is studying how well giving dasatinib together with gemcitabine hydrochloride works compared to giving gemcitabine hydrochloride alone in treating patients with pancreatic cancer previously treated with surgery.
Interventions
- OTHER laboratory biomarker analysis
- GENETIC mutation analysis
- DRUG dasatinib
- DRUG gemcitabine hydrochloride
- GENETIC nucleic acid sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-01-13 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 2 |
What the finished NCT01234935 record still lists
NCT01234935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01234935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01234935 about?
NCT01234935 is a clinical study titled "Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery". RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It i...
What is the current status of trial NCT01234935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-01-13. Estimated completion is 2017-11-27.
What interventions are being tested in trial NCT01234935?
The interventions under investigation include: laboratory biomarker analysis (OTHER), mutation analysis (GENETIC), dasatinib (DRUG), gemcitabine hydrochloride (DRUG), nucleic acid sequencing (GENETIC).
Who is sponsoring clinical trial NCT01234935?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01234935's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI